ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease

BACKGROUND: Hydroxyurea (HU) is the only disease-modifying medication for patients with sickle cell disease (SCD). HU can reduce SCD-related complications but only 35% to 50% of pediatric patients adhere to HU at the rates achieved in clinical trials and this limits its clinical effectiveness. Mobil...

Descripción completa

Detalles Bibliográficos
Autores principales: Creary, Susan, Chisolm, Deena J, O’Brien, Sarah H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2016
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067359/
https://www.ncbi.nlm.nih.gov/pubmed/27697749
http://dx.doi.org/10.2196/resprot.6403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067359/
https://www.ncbi.nlm.nih.gov/pubmed/27697749
http://dx.doi.org/10.2196/resprot.6403

Ejemplares similares